Bayer is holding off on plans to break apart the group for up to three years so new CEO Bill Anderson can focus on debt litigation, according to Reuters. There’s doubt whether enough is being done to revive the company’s finances. Last year Anderson said he was examining options to separate, spin off, or sell businesses. The drug and farm supply company will seek to strengthen the pharmaceutical development pipeline, address litigation, reduce debt, and further pursue job cuts for now.
